<DOC>
	<DOCNO>NCT01402843</DOCNO>
	<brief_summary>Pitavastatin , representative statin-series anti-dyslipidemic drug , Valsartan , representative ARB-series anti-hypertensive drug , authorize use also South Korea . They test many country prove effective safe . The concurrence dyslipidemia hypertension high rate , hence statin-series drug antihypertensive drug simultaneously administer patient . The combined administration statin-series drug CCB-series drug .</brief_summary>
	<brief_title>Efficacy , Safety Coadministered Pitavastatin Valsartan Patients With Hypertension Dyslipidemia</brief_title>
	<detailed_description>This clinical trial conduct evaluate safety effectiveness combine administration Pitavastatin Valsartan ethnic Koreans dyslipidemia concurrent hypertension , well research influence pharmacodynamic interaction two drug .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Pitavastatin</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>1 . Patients age 20 old 2 . Patients Dyslipidemia 3 . Patients hypertension 4 . Patients voluntarily sign consent form . 1 . Blood Pressure In case sit systolic blood pressure difference 20mmHg sit diastolic blood pressure 10mmHg select arm . Patients symptomatic orthostatic hypotension . Patients history Secondary hypertension suspect Secondary hypertension , e.g. , aortic coarctation , hyperaldosteronism , renal artery stenosis , Cushing 's disease , pheochromocytoma , polycystic renal disease , etc . 2 . Patients severe heart disease ( NYHA classIII IV ) , ischemic heart disease ( angina pectoris myocardial infarction ) peripheral vascular disease , patient undergo percutaneous transluminal coronary angioplasty ( PTCA ) treatment coronary artery bypass graft within 6 month . 3 . Patients clinically significant ventricular tachycardia atrial fibrillation atrial flutter , patient arrhythmia judge clinically significant investigator . 4 . Patients hypertrophic obstructive cardiomyopathy , severe obstructive CAD , aortic stenosis hemodynamically significant aortostenosis mitral stenosis . 5 . Patients severe cerebrovascular disease . 6 . Patients severe malignant retinosis . 7 . Patients consumption diseases autoimmune disease connective tissue diseases 8 . Patients endocrine metabolic disease know affect serum lipid lipoprotein . Patients uncontrollable diabetes Patients uncontrollable thyroid dysfunction 9 . Patients underwent treatment may affect lipid clinical trial . 10 . Patients history myopathy rhabdomyolysis . 11 . Patients severe renal disorder hepatic disorder . 12 . Patients gastrointestinal disease may affect drug absorption , distribution , metabolism excretion underwent operation , patient present active gastritis gastrointestinal hemorrhage proctorrhagia active inflammatory bowel syndrome occur within 12 month . 13 . All patient chronic inflammatory disease whereto antiinflammatory treatment need apply . 14 . Patients history drug alcohol abuse . 15 . Pregnant woman and/or woman lactation period childbearing period . 16 . Patients hypersensitive Pitavastatin Valsartan . 17 . Patients take investigational drug within 3 month undergo screen test clinical trial . 18 . Patients judge unsuitable clinical trial investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>phase III combination study</keyword>
</DOC>